News
- Author:
- Nick Mulcahy
Publish date: January 6, 2022
“The mole on the back of your neck is possibly cancerous. Please go see a doctor!”
News
- Author:
- Nick Mulcahy
Publish date: December 2, 2021
“The approval will help clinicians address unmet patient needs by reducing the administration time from hours to just minutes and reducing the freq...
News
- Author:
- Nick Mulcahy
Publish date: December 1, 2021
An important study of an investigational oral agent for postmenopausal women who have been treated for ER positive advanced breast cancer headlines...
News
- Author:
- Nick Mulcahy
Publish date: December 1, 2021
This advice aligns closely with the group’s initial recommendation, published over a decade ago.
News
- Author:
- Nick Mulcahy
Publish date: November 30, 2021
Drug inventor Philip Low, PhD, said the agent causes ovarian cancer lesions to “light up like stars against a night sky.”
News
- Author:
- Nick Mulcahy
Publish date: November 16, 2021
Sotorasib is an inhibitor of KRAS G12C, an oncogenic driver of tumorigenesis.
News
- Author:
- Nick Mulcahy
Publish date: November 15, 2021
“To suggest for a millisecond that active surveillance isn’t the preferred method for low-risk men is bizarre thinking ... Is this 1980?”
News
- Author:
- Nick Mulcahy
Publish date: November 8, 2021
Harvard physician says TMIST is underpowered and as a result, may be misleading.
News
- Author:
- Nick Mulcahy
Publish date: October 20, 2021
A little may go a long way, as research to date “suggests only small amounts may be needed to gain potential benefits.”
News
- Author:
- Nick Mulcahy
Publish date: October 6, 2021
“This is a meaningful advance because roughly half of all adults with B-ALL will relapse on currently available therapies.”
News
- Author:
- Nick Mulcahy
Publish date: September 29, 2021
“This is something of a phenomenon — this doctor is so beloved in this community. We will not give up.”
News
- Author:
- Nick Mulcahy
Publish date: September 21, 2021
“I think that if Texas officials understood that when they pass laws inhospitable to women, we will not hold a major conference about women’s healt...
News
- Author:
- Nick Mulcahy
Publish date: September 20, 2021
Experts say discontinuing atezolizumab is not advised if a patient is responding or is stable.
News
- Author:
- Nick Mulcahy
Publish date: September 20, 2021
Approvals include pralsetinib for non-small cell lung cancer, ripretinib for advanced gastrointestinal stromal tumor, and zanubrutinib for Waldenst...
News
- Author:
- Nick Mulcahy
Publish date: September 20, 2021
Mobocertinib is the first oral tyrosine kinase inhibitor for patients with metastatic non–small cell lung cancer who have an EGFR Exon 20 insertion...
